Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT00390221 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00390221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00390221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
August 31, 2011
Enrollment
621 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis